Human Kaposi's sarcoma cell-mediated tumorigenesis in human immunodeficiency type 1 Tat-expressing transgenic mice

Journal of the National Cancer Institute

Volumn 92, Issue 9, 2000, Pages 721-728

  Prakash, Om ^a   Tang, Zhen Ya ^a   He, You E ^a   Ali, Manzoor S ^a   Coleman, Roy ^a   Gill, Javed ^a   Farr, Gist ^a   Samaniego, Felipe ^b,c  

^a OCHSNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MESSENGER RNA; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; KAPOSI SARCOMA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; TRANSGENIC MOUSE; VIRUS CARCINOGENESIS;

EID: 0034600301     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.9.721     Document Type: Article

References (61)

1. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990;335: 123-8.
2. Gallo RC. The enigmas of Kaposi's sarcoma. Science 1998;282:1837-9.
3. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988;335:606-11.
4. Samaniego F, Gallo RC. Immunopathogenesis of Kaposi's sarcoma. In: Gupta S, editor. Immunology of HIV infection. New York (NY). Plenum Press; 1996. p. 437-50.
5. Jones KA, Peterlin MB. Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994,63:717-43.
6. Brake DA, Debouck C, Biesecker G. Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J Cell Biol 1990;111:1275-81.
7. Barillari G, Gendelman R, Gallo RC, Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993;90:7941-5.
8. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990;345:84-6.
9. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993;67:277-87.
10. Barillari G, Buonaguro L, Fiorelli V, Hoffman J, Michaels F, Gallo RC, et al. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications of AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1992;149:3727-34.
11. Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 1994;371:674-80.
12. Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P, et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS 1994;8:1237-44.
13. Corallini A, Altavilla G, Pozzi L, Bignozzi F, Negrini M, Rimessi P, et al. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res 1993; 53:5569-75.
14. Corallini A, Campioni D, Rossi C, Albini A, Possati L, Rusnati M, et al. Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS 1996;10: 701-10.
15. Albini A, Benelli R, Presta M, Rusnati M, Ziche M, Rubartelli A, et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996;12:289-97.
16. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997;11:1421-31.
17. Albini A, Soldi R, Giunciuglin D, Giraudo E, Benelli R, Primo L, et al. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996;2:1371-5.
18. Galea P, Frances V, Dou-Dameche L, Sampol J, Chermann JC. Role of Kaposi's sarcoma cells in recruitment of circulating leukocytes: implications in pathogenesis. J Hum Virol 1998;1:273-81.
19. Weeks BS. The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinase secretion in AIDS pathogenesis. Int J Mol Med 1998;1:361-6.
20. Weeks BS, Klotman ME, Holloway E, Stetler-Stevenson WG, Kleinman HK, Klotman PE. HIV-1 infection stimulates T cell invasiveness and synthesis of the 92-kDa type IV collagenase. AIDS Res Hum Retroviruses 1993;9:513-8.
21. Chapel C, Camara V, Clayette P, Salvat S, Mabondzo A, Leblond V, et al. Modulations of 92 kDa gelatinase B and its inhibitors are associated with HIV-1 infection in human macrophage cultures. Biochem Biophys Res Commun 1994;204:1272-8.
22. Dhawan S, Weeks BS, Soderland C, Schnaper HW, Toro LA, Asthana SP, et al. HIV-1 infection alters monocyte interactions with human microvascular endothelial cells. J Immunol 1995;154:422-32.
23. Lafrenie RM, Wahl LM, Epstein JS, Hewlett IK, Yamada K, Dhawan S. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J Immunol 1996;156:1638-45.
24. Prakash O, Teng S, Ali M, Zhu X, Coleman R, Dabdoub RA, et al. The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice. Arch Biochem Biophys 1997; 343:173-80.
25. Siegal B, Levinton-Kriss S, Schiffer A, Sayar J, Engelberg I, Vonsover A, et al. Kaposi's sarcoma in immunosuppression. Possibly the result of a dual viral infection. Cancer 1990;65:492-8.
26. Popescu NC, Zimonjic DB, Leventon-Kriss S, Bryant JL, Lunardi-Iskandar Y, Gallo RC. Deletion and translocation involving chromosome 3 (p14) in two tumorigenic Kaposi's sarcoma cell lines. J Natl Cancer Inst 1996;88: 450-5.
27. Herndier BG, Werner A, Arnstein P, Abbey NW, Demartis F, Cohen RL, et al. Characterization of human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. AIDS 1994;8:575-81.
28. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, et al. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 1983;131:2445-51.
29. Araujo FG. Depletion of L3T4+ (CD4+) T lymphocytes prevents development of resistance to Toxoplasma gondii in mice. Infect Immun 1991; 59:1614-9.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
31. Arya SK, Guo C, Josephs SF, Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985;229:69-73.
32. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988;55:1189-93.
33. Daniel WW. Comparison of means. In: Biostatistics: a foundation for analysis in the health sciences. New York (NY): John Wiley & Sons; 1978. p. 120-59.
34. Baeuerle PA. Baltimore D. NF-KB: ten years after. Cell 1996;87:13-20.
35. Ghosh S, May MJ, Kopp EB, NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16: 225-60.
36. Conant K, Ma M, Nath A, Major EO. Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-kappa B binding and protein kinase C activity in primary human astrocytes. J Virol 1996;70:1384-9.
37. Ramazzotti E, Vignoli M, Re MC, Furlini G, La Placa M. Enhanced nuclear factor-kappa B activation induced by tumour necrosis factor-alpha in stably tat-transfected cells is associated with the presence of cell-surface-bound Tat protein. AIDS 1996;10:455-61.
38. Kelly GD, Ensoli B, Gunthel CJ, Offermann MK. Purified Tat induces intlammatory response genes in Kaposi's sarcoma cells. AIDS 1998;12: 1753-61.
39. Blankaert D, Simonart T, Van Vooren JP, Parent D, Liesnard C, Farber CM, et al. Constitutive release of metalloproteinase-9 (92-kd type IV collagenase) by Kaposi's sarcoma cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:203-9.
40. Jeffrey JJ. Interstitial collagenases. In: Parks WC, Mecham RP, editors. Matrix metalloproteinases. San Diego (CA): Academic Press; 1998. p. 15-42.
41. Galea P, Lebranchu Y, Thibault G, Bardos P. Interleukin 4 and tumour necrosis factor alpha induce different adhesion pathways in endothelial cells for the binding of peripheral blood lymphocytes. Scand J Immunol 1992;36:575-85.
42. Yang J, Xu Y, Zhu C, Hagan MK, Lawley T, Offermann MK. Regulation of adhesion molecule expression in Kaposi's sarcoma cells. J Immunol 1994;152:361-73.
43. Taub DD. Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine Growth Factor Rev 1996;7:355-76.
44. Ensoli B, Barillari G, Buonaguro L, Gallo RC. Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma. Adv Exp Med Biol 1991;303:27-38.
45. Samaniego F, Markham PD, Gallo RC, Ensoli B. Inflammatory cytokines induce AIDS-Kaposi's sarcoma-derived spindle cells to produce and release basic fibroblast growth factor and enhance Kaposi's sarcoma-like lesion formation in nude mice. J Immunol 1995;154:3582-92.
46. Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 1997;159:4077-83.
47. Westendorp MO, Li-Weber M, Frank RW, Krammer PH. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 1994;68:4177-85.
48. Scala G, Ruocco MR, Ambrosino C, Mallardo M, Giordano V, Baldassarre F, et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 1994;179:961-71.
49. Sastry KJ, Reddy HR, Pandita R, Totpal K, Aggarwal BB. HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line. J Biol Chem 1990;265:20091-3.
50. Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992;66:7159-67.
51. Brady HJ, Abraham DJ, Pennington DJ, Miles CG, Jenkins S, Dzierzak EA. Altered cytokine expression in T lymphocytes from human immunodeficiency virus Tat transgenic mice. J Virol 1995;69:7622-9.
52. Garza HH Jr, Prakash O, Carr DJ. Aberrant regulation of cytokines in HIV-1 TAT72-transgenic mice. J Immunol 1996;156:3631-7.
53. Kundu RK, Sangiorgi F, Wu LY, Pattengale PK, Hinton DR, Gill PS, et al. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood 1999; 94:275-82.
54. Westendorp MO, Shatrov VA. Schulze-Osthoff K, Frank R, Kraft M, Los M, et al. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J 1995;14:546-54.
55. Baeuerle PA, Baltimore D. A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. Genes Dev 1989;3: 1689-98.
56. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141-79.
57. Wulczyn FG, Krappmann D, Scheidereit C. The NF-kappa B/Re1 and I kappa B gene families: mediators of immune response and inflammation. J Mol Med 1996;74:749-69.
58. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, et al. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-60.
59. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-kappaB-Re1A activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-9.
60. Ganju RK, Munshi N, Nair BC, Liu ZY, Gill P, Groopman JE. Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol 1998;72:6131-7.
61. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 1997;94: 979-84.